Tianasen (ASO-GNAO1) treatment for children with GNAO1-related epilepsy and movement problems
Official title: An Open-Label, Non-Randomized Study to Evaluate the Efficacy and Safety of ASO-GNAO1 (Tianasen) in Patients With GNAO1-Encephalopathy With Epilepsy and Movement Disorders Following Repeated Intrathecal Dose Escalation.
Run by Pirogov Russian National Research Medical University · NCT07363603 · Data updated 2026-11-12
Tianasen is being tried as an antisense drug given into the spine to see if it helps children with the GNAO1 c.607G>A mutation who have epilepsy and disabling movement disorders.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 1 Year to 14 Years |
| Sex | All |
| Enrollment | 5 (estimated) |
| Sponsor | Pirogov Russian National Research Medical University Academic / other |
| Locations | 1 site (Moscow) |
| Status | Recruiting |
| Started | September 9, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | January 23, 2026 |
| Trial ID | NCT07363603 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 1 to 14 with a confirmed c.607G>A GNAO1 variant and clinical epilepsy plus movement disorders that have been resistant to standard treatments are the intended participants.
✕Probably not a fit
Patients without the c.607G>A GNAO1 variant, those older than the enrollment age range, or those whose symptoms are due to unrelated causes are unlikely to benefit from this allele-specific therapy.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open-label, phase 1/2 dose-escalation study gives allele-specific antisense oligonucleotide (ASO-GNAO1, Tianasen) by intrathecal injection to pediatric patients over a 12-month period. All participants receive the active drug and undergo frequent neurological exams, biomarker testing, and safety monitoring to determine tolerability and an appropriate therapeutic dose. The investigational ASO is designed to selectively suppress the mutant GNAO1 mRNA (c.607G>A) while sparing the wild-type allele, based on in vitro data showing ~85% mutant suppression. The trial is single-center and focuses on children with both drug-resistant epilepsy and hyperkinetic movement disorders caused by the specified GNAO1 variant.
Why it matters
Potential benefit: If successful, Tianasen could reduce seizures, lessen abnormal movements, and slow or halt progression of neurological decline in affected children.
How similar studies have gone: Allele-specific and personalized ASO approaches have precedent (for example Milasen and approved ASOs in other diseases) and ASO-GNAO1 shows promising preclinical allele-specific suppression, but clinical efficacy for this GNAO1 variant is novel and unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed Consent: Written informed consent from the parent(s) or legal guardian(s) of the patient and the child's assent (where applicable based on age and cognitive ability), obtained prior to the initiation of any study-related procedures. * Age: Male or female children aged 1 year and older (≥1 year) until 14 years at the time of informed consent signing. * Diagnosis: A confirmed a c.607G\>A variant in of GNAO1 gene based on genetic testing, and a clinical presentation that includes both epilepsy and movement disorders. * Treatment Resistance: * For seizures: Documented resistance to antiseizure medications prior to screening, defined as the persistence of seizures despite adequate trials of at least two appropriately dosed antiseizure medications. * For non-epileptic hyperkinesias/dystonia: Documented resistance to anti-hyperkinetic medications prior to screening, defined as the persistence of debilitating hyperkinesias or dystonic attacks despite adequate trials of at least two appropriately dosed anti-hyperkinetic medications. * Contraception (for females of reproductive potential): For post- menarche female adolescents, a negative serum or urine pregnancy test at screening and agreement to use highly effective methods of contraception (e.g., hormonal implants, combined oral contraceptives, intrauterine device) throughout the study participation period. Exclusion Criteria: * Unacceptable Risk: Any concurrent severe medical, neurological, or psychiatric condition, or any other significant circumstance (e.g., unstable clinical status) that, in the judgment of the Investigator, could significantly increase the risk associated with study participation or the administration of the investigational product, or could interfere with the interpretation of study results. * Impossibility of Intervention: Any anatomical abnormality, coagulation disorder, active infection, or other condition that constitutes a contraindication to or precludes the safe performance of repeated lumbar punctures for intrathecal administration of the study drug. * Pregnancy or Lactation: Pregnancy, lactation, or intention to become pregnant during the study period. * Concurrent Experimental Therapy: Receipt of any other investigational drug, device, or biological product within 1 month prior to screening or within a period of at least 5 half-lives of that product (whichever is longer). * Protocol Compliance: Any other disease, condition, or behavioral factor that, in the opinion of the Investigator, could compromise the patient's safety, preclude adherence to the protocol schedule, or interfere with the study conduct and endpoint assessments. Age: 14 years and older
Where it's running
-
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
Moscow, Russia Recruiting
Study contacts
- Principal investigator: Elena D Belousova, Prof — Pirogov Russian National Research Medical University
- Study coordinator: Artem A Sharkov
- Email: a.sharkov@pedklin.ru
- Phone: +7 (499) 487-54-51
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
RAP-219 long-acting injectable safety and PK study in healthy adults
This early study tests RAP-219-LAI in healthy adults to see how it behaves in the body and whether it is safe and tolerable.
-
Why People with Epilepsy Get More Infections
This study tests whether anti-seizure medicines affect immune function and infection risk in people with epilepsy.
-
Long-Term Epilepsy Outcomes in Children After Perinatal Stroke
This study looks at how epilepsy progresses in kids who had a stroke before 28 days old to see how their seizures and syndromes evolve over time.
-
Hypothalamus structure and heart autonomic changes in drug-resistant epilepsy
This study tests whether structural changes in the hypothalamus relate to cardiac autonomic dysfunction in adults with drug-resistant epilepsy.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Advanced 7T fMRI for brain function in epilepsy and brain injuries
This study tests ultra-high-field brain scans at 7T to see if they can better map brain function in adults with epilepsy or brain lesions and in healthy volunteers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.